Professor Risteárd Ó Laoide:

The market is small. Mr. Michael McCarthy mentioned the other day that, in Ireland, a lot of the companies are not putting their drugs through the system, a system which he referred to as “robust”. There are rare cancers with small patient cohorts where orphan drugs are in use, but those drugs are not being put through the market because of the size of our market. There are current engagements taking place in that regard.